FDA Gets $91 Million Boost, Sequestered User Fees In 2014 Appropriation
This article was originally published in The Rose Sheet
A 2014 omnibus appropriations bill agreed to by Senate and House appropriators would give FDA $2.55 billion in discretionary funding, a $91 million increase. The bill would also make available $85 million in previously sequestered FDA user fees.
You may also be interested in...
Collecting user fees from cosmetics manufacturers to the tune of $19 million would help “improve FDA’s capacity to promote greater safety and understanding of cosmetic products,” the agency says. FDA submitted a similar proposal last year and will be up against challenges again in securing the necessary legislation.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.